Ad
Thursday, 5 January 2017
Novartis joins forces with Ionis on cardiovascular treatments
ZURICH (Reuters) - Novartis has agreed with Ionis Pharmaceuticals Inc and its affiliate Akcea Therapeutics Inc to license two experimental treatments that aim to reduce cardiovascular risk in patients with high levels of lipoproteins, the Swiss drugmaker said on Friday.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment